AEX 2
Alternative Names: AEX-2Latest Information Update: 22 Mar 2024
At a glance
- Originator Aexon Labs
- Developer Aexon Labs; NLS Pharmaceutics Ltd
- Class Sleep disorder therapies
- Mechanism of Action Orexin receptor type 1 agonists; Orexin receptor type 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Narcolepsy; Neurodegenerative disorders
Most Recent Events
- 20 Mar 2024 AEX 2 licensed to NLS Pharmaceutics worldwide
- 20 Mar 2024 Aexon Labs plans a phase-I first-in-human and phase-Ib proof-of-concept (POC) studies, in early 2025
- 01 Dec 2023 NLS Pharmaceutics enters into an option agreement with Aexon Labs to develop and commercialize Dual Orexin Receptor Agonists for Narcolepsy and Neurodegenerative disorders (9409268; 9406850)